Text Size

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

This study has been completed.
Sponsor:
Information provided by:
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00018278
First received: July 3, 2001
Last updated: January 20, 2009
Last verified: December 2004
History of Changes
  Purpose

The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.


Condition Intervention Phase
Alzheimer Disease
 Drug: Aricept
Drug: Exelon
Drug: Nicoderm Patch
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Department of Veterans Affairs:

Study Start Date: October 1998
Estimated Study Completion Date: September 2001
  Eligibility

Ages Eligible for Study:   55 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Patients diagnosed with mild to moderate probable Alzheimer's disease (mini-mental state exam scores between 15-27), and normal controls (age generally between 60-85). Subjects must either be planning to start daily cholinesterase therapy (e.g. Aricept, Exelon) or willing to try a transdermal nicotine patch for two 8 hour periods.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00018278

Locations
United States, California
Department of Veterans Affairs
San Diego, California, United States, 92161
Sponsors and Collaborators
Department of Veterans Affairs
Investigators
Investigator: Vincente Iragui, M.D., Ph.D
Investigator: Shuanna Morris, Ph.D.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00018278     History of Changes
Other Study ID Numbers: AGCG-004-98S
Study First Received: July 3, 2001
Last Updated: January 20, 2009
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Rivastigmine
Donepezil
Cholinesterase Inhibitors
 Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuroprotective Agents
Protective Agents
Central Nervous System Agents
Therapeutic Uses
Nootropic Agents

ClinicalTrials.gov processed this record on May 23, 2013